ABSTRACT
A noninterventional study under real-life conditions comparing patients receiving prolonged-release oral oxycodone/naloxone with those receiving other World Health Organization (WHO) Step III opioids found patients in the oxycodone/naloxone group had greater quality of life and less low back pain after 12 months. Oxycodone/naloxone was also found to be more cost-effective in the study.